Analysts: Why United Therapeutics has had a streak of licensing deals
Analysts: Why United Therapeutics has had a
streak of licensing deals
United Therapeutics Corp. has been striking more licensing deals this year, a trend some analysts say illustrates the company’s strategy to staying ahead of generic competition. The Silver Spring drugmaker announced a global licensing agreement earlier this month with California company Arena Pharmaceuticals Inc. (NASDAQ: ARNA). United Therapeutics (NASDAQ: UTHR) will pay Arena $800 million upfront, plus up to $400 million in milestone payments, for exclusive rights to ralinepag, a phase 3 investigational drug candidate in development for pulmonary arterial hypertension.
Story continues